Description
Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta. Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models, has selective inhibitory activity towards cyclooxygenase-2 (COX-2). Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways.
Product information
CAS Number: 65497-07-6
Molecular Weight: 826.96
Formula: C42H66O16
Chemical Name: (2S,4aR,6aS,6bR,8aR,9R,10R,11S,12aR,12bR,14bS)-8a,12b,14b-trihydrogenio-10-{[(2S,3R,4R,5R)-2-hydrogenio-5-{[(2S,3R,4S,5S,6R)-2-hydrogenio-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,4-dihydroxyoxan-2-yl]oxy}-11-hydroxy-9-(hydroxymethyl)-2-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid
Smiles: COC(=O)[C@]1(C)C[C@H]2C3=CC[C@H]4[C@@](C)(CC[C@H]5[C@](C)(CO)[C@@H](O[C@@H]6OC[C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@@H](O)C[C@]45C)[C@]3(C)CC[C@]2(CC1)C(O)=O
InChiKey: ZMXKPCHQLHYTHY-OWRBLJEPSA-N
InChi: InChI=1S/C42H66O16/c1-37(36(53)54-6)11-13-42(35(51)52)14-12-40(4)20(21(42)15-37)7-8-26-38(2)16-22(45)32(39(3,19-44)25(38)9-10-41(26,40)5)58-33-30(49)28(47)24(18-55-33)57-34-31(50)29(48)27(46)23(17-43)56-34/h7,21-34,43-50H,8-19H2,1-6H3,(H,51,52)/t21-,22-,23+,24+,25+,26+,27+,28-,29-,30+,31+,32-,33-,34-,37-,38-,39-,40+,41+,42-/m0/s1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : 100 mg/mL (120.92 mM; Need ultrasonic).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
Esculentoside A (0-10 μM; 24 hours) reduced the release of TNF concentration in primed macrophages .
In Vivo:
Esculentoside A (EsA) (intraperitoneal injection; 20 mg/kg; once a day; 4 weeks) plays significant roles in the treatment of BXSB mice through modulation of inflammatory cytokines, inhibition of renal cell proliferation and induction of apoptosis . Esculentoside A (EsA) (injected intraperitoneally; 5, 10 and 20 mg/kg; once a day; 7 days) dose-dependently decreases the TNF, IL-1 and IL-6 levels in the sera of mice following LPS challenge.
References:
- Wu F, et al. Synthesis, in vitro inhibitory activity towards COX-2 and haemolytic activity of derivatives of esculentoside A. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6430-3. Epub 2007 Oct 5.
- Ma H, et al. The effect of esculentoside A on lupus nephritis-prone BXSB mice. Arch Med Sci. 2013 Apr 20;9(2):354-60.
- Zhong WT, et al. Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice. J Surg Res. 2013 Nov;185(1):364-72.
- Ju DW, et al. Esculentoside A inhibits tumor necrosis factor, interleukin-1, and interleukin-6 production induced by lipopolysaccharide in mice. Pharmacology. 1998 Apr;56(4):187-95
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.